Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US6323071042
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG001J1BQ86
NTRA
Natera Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Diagnostics & Research · THEMEFOLIO: $PLNG
NAME
Natera Inc
ISIN
US6323071042
TICKER
NTRA
MIC
XNAS
REUTERS
NTRA.OQ
BLOOMBERG
NTRA US
Wed, 22.01.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23 – 25, 2025 in San Francisco, CA. BESPOKE CR...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its CEO, Steve Chapman, has been selected as one of the top healthcare technology CEOs for 2024, as determined by Healthcare Technology Report. Chapman was also named “BioTechnology Innovator of the Year” in 2024, in the fourth annual BioTech Br...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.01.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will provide an update to the investment community, today, at the 43rd annual J.P. Morgan Healthcare Conference. In addition to its previously announced preliminary financial results for the fourth quarter and year ended Dec. 31, 2024, the Company will also present details on i...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.01.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. The Company expects the following: Total revenues of approximately $472 million in the fourth quarter of 2024 compared to $311 million in the fourth quarter...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.01.2025       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, Jan. 15, 2025 at 9:00 a.m. PT (12:00 p.m. ET). Members of management will deliver a presentation and host a Q&A with the investment community at...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.12.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests. On December 10, 2024, the District Court for the Middle District of North Carolina (“The District Court”) granted Natera’s request to inc...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.12.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC Institute of Molecular Oncology (IFOM-ETS) and funded by the European Union Horizon Europe Programme, SAGITTARIUS is a global, randomized, phase III clinica...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.12.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling company, today announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. iPRS, which reports 5-year and lifetime breast cancer ris...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.12.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that Obstetrics & Gynecology (also known as The Green Journal) published the Company’s clinical validation study on its cell-free DNA (cfDNA) Fetal RhD noninvasive prenatal test (Fetal RhD NIPT). Natera’s study is the largest clinical validatio...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage applies to SLT patients i...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 26.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 10-13 in San Antonio, TX. Natera and its collaborators will present a total of six abstracts. “We are proud to share this new data on Si...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement: In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more than three years ago about Guardant’s Reveal test. Today, a jury issued a decision in Guardant...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its co-founder and executive chairman, Matthew Rabinowitz, PhD, has been named R&D Leader of the Year by R&D World. Established in 1963, the R&D 100 Awards program identifies and celebrates the top 100 revolutionary technologies of...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Multiple validation studies on Signatera have been published in top-tier journal...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the third quarter ended September 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $439.8 million in the third quarter of 2024, compared to $268.3 million in the third quarter of 2023, a re...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. CALGB (Alliance)/SWOG 80702 evaluated the benefit of adding celecoxib to FOLFOX in postoperative treatment of stage III colorectal ca...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the following investor conferences in November and December. The UBS Global Healthcare Conference on Thursday, Nov. 14 at 11:00 am ET | 8:00 am PT in Rancho Palos Verdes, CA. The Wolfe Research...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 01.11.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its third quarter ended Sept. 30, 2024, after the market closes on Nov. 12, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Tue, 22.10.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its 385-gene kidney genetic test, Renasight™, at the annual meeting of the American Society of Nephrology (ASN) Kidney Week 2024. The meeting will take place in San Diego from Oct. 23-27. Natera and...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.09.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today issued the following statement regarding its ongoing patent infringement litigation with NeoGenomics in response to inquiries: On Sept. 23, 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGe...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 16.09.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the simultaneous publication of three peer-reviewed papers, crossing a milestone of more than 85 peer-reviewed publications on Signatera. This includes: Groundbreaking colorectal cancer (CRC) data from the GALAXY arm of the ongoing CIRCULATE-Japan...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Sat, 14.09.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is one of the largest and most comprehensive prospective studies...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.09.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain. Natera and its collabor...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 28.08.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of its leadership team will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4 at 2:35 pm ET | 11:35 am PT in New York City. A live webcast and audio archive of the event may be accessed throug...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.08.2024       Natera
US6323071042

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an inc...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 06.12.2023       Natera
US6323071042

New York, New York--(Newsfile Corp. - December 6, 2023) -  Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, continues to investigate whether certain directors and officers of Natera, Inc. ("Natera") (NASDAQ: NTRA) breached their fiduciary duties to Natera and its shareholders....
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.11.2023       Natera
US6323071042

New York, New York--(Newsfile Corp. - November 20, 2023) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, continues to investigate whether certain directors and officers of Natera, Inc. ("Natera") (NASDAQ: NTRA) breached their fiduciary duties to Natera and its shareholders. If yo...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.11.2023       Natera
US6323071042

New York, New York--(Newsfile Corp. - November 9, 2023) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, continues to investigate whether certain directors and officers of Natera, Inc. ("Natera") (NASDAQ: NTRA) breached their fiduciary duties to Natera and its shareholders. If you...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Sat, 12.08.2023       Natera
US6323071042

Philadelphia, Pennsylvania--(Newsfile Corp. - August 12, 2023) - Grabar Law Office is investigating potential claims on behalf of Natera, Inc. (NASDAQ: NTRA) shareholders. The investigation concerns whether certain officers of Natera have breached their fiduciary duties owed to the company.A federal securities fraud complaint alleges that Natera, t...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.02.2023       Natera
US6323071042

Philadelphia, Pennsylvania--(Newsfile Corp. - February 27, 2023) - Grabar Law Office is investigating potential claims on behalf of Natera, Inc. (NASDAQ: NTRA) shareholders. The investigation concerns whether certain officers of Generac have breached their fiduciary duties owed to the company.Natera, Inc. offers genetic testing in the areas of wome...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.01.2023       Natera
US6323071042

Wilmington, Delaware--(Newsfile Corp. - January 18, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Natera, Inc. (NasdaqGS: NTRA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-natera-inc.To contact Seth D. Rigrodsky or Gina...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.08.2022       Natera
US6323071042

Wilmington, Delaware--(Newsfile Corp. - August 2, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Natera, Inc. (NASDAQ: NTRA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-natera-inc.To contact Seth D. Rigrodsky or Gina M. S...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 27, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Natera, Inc. ("Natera") (NASDAQ: NTRA) . This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock betwee...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.06.2022       Natera
US6323071042

San Francisco, California--(Newsfile Corp. - June 27, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now.Class Period: Feb. 26, 2020 - Apr. 19, 2022Lead Plaintiff Deadline: June 27, 2022Visit: www.hbsslaw.com/investor-fraud/NTRA Conta...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.06.2022       Natera
US6323071042

Los Angeles, California--(Newsfile Corp. - June 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. (NASDAQ: NTRA) ("Natera" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated th...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 27, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Nate...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Mon, 27.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 27, 2022) - Levi & Korsinsky, LLP notifies investors in Natera, Inc. (NASDAQ: NTRA) ("Natera" or the "Company") of a class action securities lawsuit.The lawsuit on behalf of Natera investors has been commenced in the the United States District Court for the Western District of Texas. This law...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.06.2022       Natera
US6323071042

San Francisco, California--(Newsfile Corp. - June 26, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now. Class Period: Feb. 26, 2020 - Apr. 19, 2022Lead Plaintiff Deadline: June 27, 2022Visit: www.hbsslaw.com/investor-fraud/NTRA Con...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Sun, 26.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 25, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Natera and certain of its o...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Sat, 25.06.2022       Natera
US6323071042

San Francisco, California--(Newsfile Corp. - June 25, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now. Class Period: Feb. 26, 2020 - Apr. 19, 2022Lead Plaintiff Deadline: June 27, 2022Visit: www.hbsslaw.com/investor-fraud/NTRACont...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.06.2022       Natera
US6323071042

Securities Litigation Partner Lubna M. Faruqi Encourages Investors Who Suffered Losses Exceeding $100,000 In Natera To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 24, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Natera, Inc. ("Natera"...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 24, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Nate...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 24, 2022) - Levi & Korsinsky, LLP notifies investors in Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) of a class action securities lawsuit.The lawsuit on behalf of Natera investors has been commenced in the the United States District Court for the Western District of Texas. This lawsuit is on...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.06.2022       Natera
US6323071042

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated th...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 23, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Natera, Inc. ("Natera") (NASDAQ: NTRA) . This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock betwee...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 23, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Natera, Inc. (NASDAQ: NTRA) alleging that the Company violated federal securities laws.This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Nate...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.06.2022       Natera
US6323071042

Los Angeles, California--(Newsfile Corp. - June 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Natera, Inc. ("Natera" or "the Company") (NASDAQ: NTRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated th...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Thu, 23.06.2022       Natera
US6323071042

New York, New York--(Newsfile Corp. - June 22, 2022) - Levi & Korsinsky, LLP notifies investors in Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA) of a class action securities lawsuit.The lawsuit on behalf of Natera investors has been commenced in the the United States District Court for the Western District of Texas. This lawsuit is on...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.06.2022       Natera
US6323071042

San Francisco, California--(Newsfile Corp. - June 22, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now.Class Period: Feb. 26, 2020 - Apr. 19, 2022Lead Plaintiff Deadline: June 27, 2022Visit: www.hbsslaw.com/investor-fraud/NTRAContac...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.06.2022       Natera
US6323071042

Radnor, Pennsylvania--(Newsfile Corp. - June 22, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against Natera, Inc. ("Natera") (NASDAQ: NTRA) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock betwee...
Read more
Natera
Technical Analysis Termsheets Terminal
Permalink